Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant (ARTEMIS)
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Sponsor: Marker Therapeutics, Inc.
Terminated
Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.
Other terminated trials from Marker Therapeutics, Inc.
More terminations from Marker Therapeutics, Inc.
Other Acute Myeloid Leukemia trials with similar outcome
This PHASE2 trial investigates Acute Myeloid Leukemia and Stem Cell Transplantation and is currently terminated or withdrawn. Marker Therapeutics, Inc. leads this study, which shows 18 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE2
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 13 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Marker Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .